Zongjiu Jiao
Xingtai, 054001, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
MiR-22-3p regulates the SIRT1/P53 signaling pathway, thereby influencing ferroptosis in diffuse large B-cell lymphoma cells.
Journal: Leukemia & lymphoma
Published: October 15, 2025
Zanubrutinib, lenalidomide, rituximab, temozolomide ± methotrexate as first-line treatment for primary central nervous system lymphoma: A prospective, open-label, multicentre clinical trial.
Journal: British journal of haematology
Published: July 03, 2025
Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) in elder or intensive chemotherapy ineligible patients with newly diagnosed acute myeloid leukemia.
Journal: Blood cancer journal
Published: September 24, 2024
Venetoclax combined with daunorubicin and cytarabine (2 + 6) in acute myeloid leukemia: Updated results of a phase II trial.
Journal: Hematological oncology
Published: July 23, 2024
Venetoclax combined with daunorubicin and cytarabine (2 + 6) as induction treatment in adults with newly diagnosed acute myeloid leukemia: a phase 2, multicenter, single-arm trial.
Journal: Experimental hematology & oncology
Published: March 19, 2023
miR-506 in patients with chronic myeloid leukemia and its effect on apoptosis of K562 cells.
Journal: American journal of translational research
Published: November 06, 2020
miR-497-5p induces apoptosis in K562 cells by downregulating ROCK1.
Journal: American journal of translational research
Published: October 22, 2020
Showing 1-8 of 8
Last Updated: 09/26/2026